10,272 Shares in Becton, Dickinson and Company $BDX Acquired by MASTERINVEST Kapitalanlage GmbH

MASTERINVEST Kapitalanlage GmbH bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, Holdings Channel.com reports. The fund bought 10,272 shares of the medical instruments supplier’s stock, valued at approximately $1,554,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of BDX. Auto Owners Insurance Co lifted its stake in Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after purchasing an additional 40,528,680 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $3,721,533,000. State Street Corp grew its position in shares of Becton, Dickinson and Company by 0.8% in the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock valued at $2,714,871,000 after purchasing an additional 116,737 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in shares of Becton, Dickinson and Company by 16.5% in the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after purchasing an additional 1,651,592 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Becton, Dickinson and Company by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier’s stock valued at $1,331,165,000 after purchasing an additional 53,884 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 11,869 shares of company stock worth $1,994,719. Insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Evercore set a $180.00 target price on Becton, Dickinson and Company in a research note on Monday, July 6th. Bank of America reduced their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $185.67.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $188.11 on Friday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The firm’s 50 day moving average price is $165.23 and its 200 day moving average price is $160.33. The company has a market cap of $51.83 billion, a P/E ratio of 56.66, a PEG ratio of 13.41 and a beta of 0.19. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the firm posted $3.68 earnings per share. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.